Last reviewed · How we verify
rAd-IFN
rAd-IFN is a recombinant adenovirus vector-based gene therapy that expresses interferon-alpha.
rAd-IFN is a recombinant adenovirus vector-based gene therapy that expresses interferon-alpha. Used for Metastatic renal cell carcinoma.
At a glance
| Generic name | rAd-IFN |
|---|---|
| Also known as | Nadofaragene firadenovec |
| Sponsor | Ferring Ventures Limited |
| Drug class | oncolytic virus |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This mechanism involves the use of a viral vector to deliver the interferon-alpha gene to cells, which then produce the protein to stimulate an immune response. The goal is to activate the body's immune system to fight cancer cells.
Approved indications
- Metastatic renal cell carcinoma
Common side effects
- Fatigue
- Chills
- Fever
- Headache
- Nausea
Key clinical trials
- Fatty Liver and Pancreatic Steatosis
- Treatment and Natural History Study of Lymphomatoid Granulomatosis (PHASE2)
- Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma (PHASE3)
- ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) (PHASE3)
- Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy (PHASE1, PHASE2)
- COMPArison of Screening Strategies for Active TuBerculosis (COMPASS-TB)
- Early Risk Assessment in Household Contacts (≥10 Years) of TB Patients by New Diagnostic Tests in 3 African Countries
- Latent Tuberculosis in Healthcare Workers - the Reality of a Portuguese Tertiary Hospital
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rAd-IFN CI brief — competitive landscape report
- rAd-IFN updates RSS · CI watch RSS
- Ferring Ventures Limited portfolio CI